Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone805-562-3500
Debt
Current Ratio2.77
Quick Ratio2.34
Price-To-Earnings
Sales & Book Value
Annual Sales$36.54 million
Price / Sales10.43
Price / Cash FlowN/A
Price / Book9.38
Profitability
Net Income$-64,020,000.00
Net Margins-126.03%
Return on Assets-54.84%
Miscellaneous
Employees200
OptionableOptionable
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra Inc (NASDAQ:SIEN) posted its quarterly earnings results on Tuesday, November, 6th. The medical instruments supplier reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.05. The medical instruments supplier had revenue of $16.90 million for the quarter, compared to analysts' expectations of $16.66 million. Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The business's quarterly revenue was up 72.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.74) earnings per share. View Sientra's Earnings History.
When is Sientra's next earnings date?
What price target have analysts set for SIEN?
9 brokerages have issued twelve-month price targets for Sientra's stock. Their predictions range from $16.00 to $31.00. On average, they expect Sientra's share price to reach $24.1429 in the next year. This suggests a possible upside of 82.1% from the stock's current price. View Analyst Price Targets for Sientra.
What is the consensus analysts' recommendation for Sientra?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra.
Has Sientra been receiving favorable news coverage?
Media stories about SIEN stock have been trending positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Sientra earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the company's share price in the near future.
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Establishment Labs (ESTA), RTI Surgical (RTIX), Invacare (IVC), Lakeland Industries (LAKE), ConforMIS (CFMS), Bionik Laboratories (BNKL), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Precision Therapeutics (AIPT), Histogenics (HSGX), Wound Management Technologies (WNDM), Rewalk Robotics (RWLK), Allied Healthcare Products (AHPI), Avitar (AVTI) and Halyard Health (HYH).
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 71)
- Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 47)
- Mr. Patrick F. Williams, Sr. VP & GM of miraDry (Age 45)
- Mr. Keith J. Sullivan, Director & Advisor (Age 60)
- Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 53)
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $13.26.
How big of a company is Sientra?
Sientra has a market capitalization of $393.81 million and generates $36.54 million in revenue each year. The medical instruments supplier earns $-64,020,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Sientra employs 200 workers across the globe.
What is Sientra's official website?
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (NASDAQ SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
